Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native in...
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT03318900
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Adoptive Cell Therapy Across Cancer Diagnoses
- Conditions
- Interventions
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 25
- Registration Number
- NCT03296137
- Locations
- 🇩🇰
Center for Cancer immune Therapy (CCIT), Dept. of Hematology and dept. of Oncology, Copenhagen, Denmark
Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
- Conditions
- Interventions
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT03197025
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 110
- Registration Number
- NCT03190941
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2021-09-14
- Target Recruit Count
- 41
- Registration Number
- NCT03113773
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Iltoo Pharma
- Target Recruit Count
- 100
- Registration Number
- NCT02955615
- Locations
- 🇪🇸
Hospital Universitario y Politécnico La Fe, Valencia, Spain
🇲🇽Investigación y Biomedicina, Chihuahua, Mexico
🇲🇽Clitider S.A. de C.V., Ciudad de Mexico, Mexico
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 180
- Registration Number
- NCT02858310
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 124
- Registration Number
- NCT02830724
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
IL-2 in Refractory Autoimmune Encephalitis
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT02714959
T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System
- First Posted Date
- 2016-01-25
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Yi Miao
- Target Recruit Count
- 6
- Registration Number
- NCT02662348
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.